IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights
IceCure Medical to Report H1 2022 Results and Conduct Conference Call on August 15, 2022
IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors
IceCure is setting new standards in minimally-invasive tumor therapy for women’s health and interventional oncology. Founded in 2006 to advance the treatment of cancerous tumors, our core technology is based on cryoablation, using liquid nitrogen to create ultra-low freezing temperatures to destroy tumors safely, quickly, and painlessly in a minimally-invasive procedure.
Our ProSense™ cryoablation system, enables rapid minimally-invasive, safe, and effective treatment of breast lesions in-office or ambulatory hospital settings. The system provides physicians with full control over the procedure, ensuring that the treated zone is destroyed while leaving surrounding tissue undamaged. The ProSense™ system is a proven solution for the treatment of benign and malignant breast tumors, as well as renal, lung, and bone cancer. The FDA cleared and CE marked ProSense system is available in the US, Europe, and across Asia in Singapore, Thailand, Japan, and Taiwan.
IceCure Medical Ltd.
7 Ha’Eshel Street
PO Box 3163
IceCure Medical, LTD
CFO / COO
7 Ha'Eshel St
PO Box 3163
VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598